RT @Pharmafocus: Novartis signs $90m deal with Oxford BioMedica: http://t.co/NjKhE3vumo #oncology #cancer #pharma #health
Oxford BioMedica is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs.
We have world-class expertise in gene therapy and immunotherapy and significant technical experience with the LentiVector® platform which, together, has underpinned a successful track record to date in bringing novel gene-based products into clinical development.
Our world-class facilities provide the full range of services for developing innovative gene-based medicines and therapeutic vaccines from proof of concept through GMP manufacture and supply for clinical trials.
We are keen to apply our knowledge and experience to new areas of development in order to maximise value from future partnerships and alliances.
OXB Solutions is an online portal designed to support Oxford BioMedica's alliances in GMP manufacturing, translational research, clinical development and intellectual property relating to bringing novel gene-based therapies to market. Our capabilities cover the entire product lifecycle; from pre-clinical development, to regulatory support, to all future stages of viral vector product clinical development and commercial scale.
We recognise the importance of strong relationships and industry alliances in delivering success. Together, we can create strategies to develop novel and cost effective supply solutions such as bulk drug substance manufacture, fill/finish, GMP certification and release.
See our latest news and press releases in the news section
RT @andrew_ward1: Novartis bags stake in Oxford BioMedica as UK biotech stalwart wins role in Swiss firm's "hunt & destroy" cancer drug htt…